PP
AKBA icon

PDT Partners’s Akebia Therapeutics AKBA Stock Holding History

PDT Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-433,400
Closed -$979K – 916
2021
Q4 		$979K Sell
433,400
-148,300
-25% -$404K 0.07% 362
2021
Q3 		$1.68M Sell
581,700
-2,900
-0.5% -$8.28K 0.12% 270
2021
Q2 		$2.22M Sell
584,600
-20,500
-3% -$69K 0.15% 258
2021
Q1 		$2.05M Buy
+605,100
New +$2.18M 0.15% 265
2019
Q1 		– Sell
-67,634
Closed -$374K – 433
2018
Q4 		$374K Buy
67,634
+10,748
+19% +$84.1K 0.02% 351
2018
Q3 		$502K Buy
+56,886
New +$509K 0.02% 360

Other funds holding AKBA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
OCM
Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

PDT Partners's AKBA Position: Q1 2022 in Review

PDT Partners sold out of Akebia Therapeutics (AKBA) in Q1 2022, closing a stake of 433,400 shares — an estimated $979K sold.

PDT Partners first reported a position in AKBA in Q3 2018 and held it in 6 quarters. The position peaked at $2.22M in Q2 2021. 124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

  • PDT Partners reported no remaining Akebia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • PDT Partners sold 433,400 Akebia Therapeutics shares in Q1 2022, an estimated $979K.
  • PDT Partners first reported a position in Akebia Therapeutics in Q3 2018 and held it in 6 quarters.
  • PDT Partners's Akebia Therapeutics position peaked at $2.22M in Q2 2021.
  • 124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on PDT Partners's 13F filing for Q1 2022, filed 16 May 2022.